Our latest Vital Health Podcast unpacks why tying U.S. drug prices to lower-cost international markets - a policy known as reference pricing - can backfire, undermining patient access. In this episode, @DuaneSchulthess sits with Joseph Hammang, Ph.D., Harry Bowen and @MSDEurope’s Virginia Acha to examine: - What is reference pricing?: A system that looks at prices paid abroad and asks, “Why are we paying more here? Let’s peg our price to their lower rate.” - How pharma segments markets: Companies treat regions as isolated markets, charging higher U.S. prices while using lower prices overseas to expand volume, a form of price discrimination. - The unintended consequence: If U.S. prices were tied to foreign rates, firms simply withdraw drugs from lower‑price markets, leaving no reference point and defeating the policy. - Policy implications: Effective pricing reforms must account for market isolation and the leverage companies hold to exit markets, balancing cost savings with sustainable access for patients. 🎧 Listen to the full conversation on the Vital Health Podcast: buff.ly/Ak471OS #ReferencePricing #DrugPricing #HealthcarePolicy #PillPenalty #MarketAccess @weworkforhealth

Two years running! Announcing that CanDeal DNA has won “Best Buy-Side Evaluated Pricing Service” for our #ReferencePricing Service in the @WatersTech #BuySide Technology Awards 2024. Thank you to all our clients and partners for your continued support! waterstechnology.com/awards-…

🧵1/3 Political parties claiming #reshoring #medicines is a solution for #shortages, were the 1s: 💸Claiming for #AffordableMedicines 🚪Boosting #generics entrance to market 📉Creating bottomless spiraling-down #ReferencePricing 🫰Relying on 🇨🇳🇮🇳 cheaper supplies

Patients living with #lupus & other #chronicillness depend on American medical #innovation and #access to revolutionary therapies. Foreign #referencepricing will both disrupt investment and limit our access to life saving #medications. #HR3 @RepSusieLee @RepHorsford

Patients living with #lupus & other #chronicillness depend on American medical #innovation and #access to revolutionary therapies. Foreign #referencepricing will both disrupt investment and limit our access to life saving #medications. #HR3 @StenyHoyer @ClyburnSC06 @RepLizCheney

Patients living with #lupus & other #chronicillness depend on American medical #innovation and #access to revolutionary therapies. Foreign #referencepricing will both disrupt investment and limit our access to life saving #medications. #HR3 @SpeakerPelosi @GOPLeader @SteveScalise

Had #HR3 been implemented, Americans would not have been able to receive the #COVID19 vaccine as quickly as we are now. @POTUS @SpeakerPelosi, including #referencepricing in the recent #infrastructurepackage could harm patients and biopharmaceutical innovation in the long-run.

Foreign #referencepricing schemes don’t work because we don’t have the same gov’t, policies, taxes. The @HHSGov #MFN rule just makes it harder for doctors and hospitals to provide the medicines #patients need. @RepDavidEPrice @GKButterfield @RepAdams ncbioscience.net/news/detail…

@realDonaldTrump is moving forward with the #MostFavoredNation #ExecutiveOrder. #ReferencePricing will only lead to delays in treatment, lower quality care and even fewer innovative treatments for #AmericanPatients. Stop #MFN before it harms our #patients! ow.ly/sDBM50Cofws

.@SenCortezMasto During these unprecedented times, #innovation and research are more crucial than ever for Nevada #patients. We can’t afford to sacrifice #patient health and restrict #access to innovative treatments by importing foreign price controls. #IPI #ReferencePricing #Rx

During the #COVID19 pandemic, medical #innovation and research are more critical than ever. #Patient health and access to lifesaving #treatments are negatively impacted by importing foreign #ReferencePricing. #MFN cc: @SenatorCarper @ChrisCoons

Following today's #executiveorder on #drugpricing? Listen to what @PacificResearch @sallypipes has to say about #IPI #referencepricing #pricecontrols on the @LarsLarsonShow. soundcloud.com/thelarslarson…

.@realDonaldTrump .@WhiteHouse Shortsighted approaches like #IPI will put access and new drug development at risk. The Administration must reconsider the impact of this policy and withdraw the EO. America’s patients deserve better. #ReferencePricing

"While the lost economic opportunities are meaningful, ultimately it is patients who will bear the highest costs of all." From @WayneWinegarden in @Forbes: Patients Will Suffer The Most From The Trump Administration’s #ReferencePricing Scheme buff.ly/3eVdFmq

Nothing beats a little #drugpricing discussion online with #ISPORAnnual by Incze, Garrison, Epsin, and Kali. #referencepricing #IPI

.@realDonaldTrump .@SecAzar .@joegrogan45 #IPI model would sacrifice hepatitis patients’ access to innovative medications & life saving treatments. Healthcare reform proposals that import foreign #ReferencePricing on US drugs is unacceptable & will stifle medical innovation.

.@realDonaldTrump .@SecAzar .@joegrogan45 Tying the availability of life saving #Rx medication to government set prices in foreign countries is shortsighted, dangerous, and will leave our sickest #patients with limited and diminished treatment options. #ReferencePricing #IPI

I recently spoke w/ @VitalTransform @DuaneSchulthess & @CALifeSciences Board Member @SutroBioBill to discuss the negative consequences #HR3 foreign #referencepricing #pricecontrols will have on #patients R&D coming out of #CA #lifesciences sector. Here’s our podcast: #HR3Impact

#Referencepricing is a solution all sides seem to agree on, but "the devil's in the details" according to our CEO David Henka. He chatted with @alisonkanski about the solution's potential and how it creates #drugcost savings. Read more in @MMMnews mmm-online.com/home/channel/…

Learn about #referencepricing and some of the challenges of implementing it on a national level (despite its bipartisan support) from our CEO David Henka's conversation with @alisonkanski in @MMMnews.